Vitamin B3 (niacin).

The body makes its own NAD, the coenzyme form of niacin, from the amino acid tryptophan, and one of the enzymes on that route depends on the active form of vitamin B6. Steady B6 status therefore supports how much niacin the body produces from the protein it eats.

Niacin works as the coenzyme NAD and riboflavin as the flavins FAD and FMN, the two electron-carrying coenzymes at the center of energy metabolism. NAD collects electrons in the citric acid cycle and passes them to a riboflavin-based flavin at the entry to the mitochondrial chain, so the two move energy in sequence.

NADH, the electron-loaded form of niacin's coenzyme, releases its electrons into the first complex of the mitochondrial electron transport chain, and Coenzyme Q10 is the mobile carrier that collects them and moves them onward. The two are consecutive links in the pathway that turns food into cellular energy.

The first enzyme that begins converting tryptophan into niacin's coenzyme carries a heme group and so relies on iron. Adequate iron therefore supports the body's own production of niacin from that amino acid.

About sixty milligrams of tryptophan can be converted through the kynurenine route into one milligram of niacin equivalents. Tryptophan supply therefore contributes directly to the NAD pool.

Nicotinamide riboside enters NAD synthesis through nicotinamide riboside kinase, bypassing the step niacin uses. Both converge on the same NAD pool by different entry points.

NMN sits one step from NAD in the salvage route that niacin and nicotinamide also feed. Supplying either raises flux into the same nucleotide pool.

Niacin is converted to NAD through the Preiss-Handler route, so the vitamin is the dietary form of the coenzyme itself. Every niacin-dependent function is really an NAD-dependent one.

Excess nicotinamide is cleared by nicotinamide N-methyltransferase, which consumes SAM-derived methyl groups. Betaine replenishes that methyl pool, which is why high-dose niacin products are often paired with a methyl donor.

Methylating nicotinamide for excretion draws on SAM, which the folate cycle regenerates. Folate supply supports the methyl pool that a large niacin dose taxes.

Inositol hexanicotinate is six niacin molecules esterified to one inositol, which releases nicotinic acid slowly and produces far less skin flushing. The pairing is a formulation convention rather than an added effect.

Nicotinic acid coordinates chromium, which is the chemistry behind niacin-bound chromium and the older glucose tolerance factor preparations. The two are formulated together for support of normal glucose metabolism, a convention rather than a measured additive effect.

NAD kinase phosphorylates NAD+ to NADP+ using ATP, and that reaction runs on a magnesium-ATP complex. Magnesium is also required by most of the kinases that sit upstream in glycolysis, where NAD+ acts as the electron acceptor. Neither nutrient substitutes for the other. They work in the same reaction sequence.

Alcohol dehydrogenase and several aldehyde dehydrogenases are zinc metalloenzymes that use NAD+ as their hydrogen acceptor. The catalytic zinc holds the substrate in position while the nicotinamide ring takes the hydride. This is a structural pairing inside one enzyme rather than an effect measured in a trial.

Lipoamide sits at the core of the pyruvate and alpha-ketoglutarate dehydrogenase complexes, and the third component of each complex, dihydrolipoamide dehydrogenase, re-oxidises reduced lipoamide by handing electrons to NAD+. Without NAD+ the lipoyl arm stays reduced and the complex stalls. The relationship is a fixed step in the reaction cycle.

Pantothenic acid becomes coenzyme A, the carrier that brings acetyl and acyl groups into the citric acid cycle and into fatty acid oxidation. Every turn of those cycles reduces NAD+ to NADH. The two vitamins occupy adjacent roles in the same energy-release pathway, which is why they are usually formulated together in a B complex.

Glutathione reductase restores oxidised glutathione using NADPH, which is the phosphorylated form of the NAD pool that niacin supplies. The pentose phosphate pathway generates that NADPH. Adequate niacin therefore supports the regeneration side of glutathione turnover rather than glutathione levels directly.

N-acetylcysteine supplies cysteine for glutathione synthesis while the NADPH derived from the NAD pool keeps that glutathione in its reduced state. One partner feeds the substrate side and the other the recycling side of the same antioxidant system. The pairing is mechanistic. It has not been isolated in a dedicated combination trial.

Sirtuins are NAD-dependent deacetylases: they cleave NAD+ for every deacetylation they perform, releasing nicotinamide. Resveratrol is studied as a sirtuin modulator, so its proposed target cannot operate without an available NAD+ pool. The mechanistic link is settled. The combined effect on any human outcome is not.

Pterostilbene is a dimethylated stilbene studied alongside NAD precursors for the same sirtuin-dependent reactions, and commercial formulas commonly pair the two. The rationale is that a sirtuin modulator needs substrate, and NAD+ is the substrate. Formulation practice runs ahead of the human data here.

CD38 is a major NAD-consuming enzyme, and quercetin has been characterised in laboratory work as a CD38 inhibitor. Slowing NAD breakdown while supplying precursor is a coherent pairing at the level of enzymology. Whether it changes tissue NAD in people has not been settled.

Apigenin, like quercetin, is described in laboratory work as inhibiting CD38, the enzyme that hydrolyses NAD+. Pairing it with a niacin form addresses supply and turnover at once. The evidence is cell and animal level, not human outcome level.

Excess nicotinamide is cleared by nicotinamide N-methyltransferase, which transfers a methyl group from S-adenosylmethionine and produces N1-methylnicotinamide. High nicotinamide intakes therefore draw on the methyl pool. Anyone taking large amounts of a niacin form is running that disposal route continuously.

Choline oxidises to betaine, which remethylates homocysteine to methionine and so replenishes the S-adenosylmethionine pool. That pool is what nicotinamide methylation draws down. The two nutrients meet at the methyl budget rather than at any shared receptor.

Methionine synthase needs B12 to move a methyl group from 5-methyltetrahydrofolate onto homocysteine, regenerating methionine and then S-adenosylmethionine. Nicotinamide disposal spends methyl groups from that same pool. Adequate B12 keeps the regeneration side of the ledger working.

Methionine is the direct precursor of S-adenosylmethionine, the methyl donor used to clear nicotinamide. The methylated product is excreted in urine, so the methyl group is spent rather than recycled. This is why methyl-group supply and high-dose nicotinamide are discussed together.

Endogenous creatine synthesis is one of the largest single consumers of S-adenosylmethionine methyl groups, and nicotinamide methylation draws on the same pool. Supplemental creatine reduces the body's own synthesis, which eases that draw rather than adding to it. The interaction sits at the shared methyl budget and has not been quantified in a combination trial.

Building NAD from nicotinamide or nicotinic acid requires phosphoribosyl pyrophosphate, which is made from ribose-5-phosphate in the pentose phosphate pathway. Ribose supplies the sugar half of the dinucleotide. The vitamin supplies the base half.

NAD synthetase completes the final step of the de novo and Preiss-Handler routes by transferring an amide nitrogen from glutamine onto nicotinic acid adenine dinucleotide. Without that nitrogen donor the molecule stops one step short of NAD. Glutamine is abundant in most diets, so this is pathway architecture rather than a common shortfall.

Tryptophan can go down the kynurenine route toward niacin or down the hydroxylation route toward serotonin, and the two compete for the same amino acid. Adequate dietary niacin reduces the demand for tryptophan as a niacin source. 5-HTP enters after the branch point, so it bypasses the competition entirely.

Nicotinic acid and marine omega-3 fatty acids both act on hepatic triglyceride handling, by different routes: one through adipose lipolysis and hepatic VLDL assembly, the other through reduced triglyceride synthesis and increased fatty acid oxidation. Combined use is a recognised formulation pattern for supporting normal blood lipid levels. The effects are on lipid markers.

Red yeast rice contains monacolin K, which acts on hepatic cholesterol synthesis, while nicotinic acid acts on lipoprotein assembly and clearance. Stacking two agents that both influence lipid handling is a documented pharmacology consideration rather than a free addition, and muscle-related complaints are the usual thing clinicians watch for. This pairing warrants clinician oversight.

The cutaneous flushing from nicotinic acid is driven by prostaglandin D2 released from skin cells, which is why cyclooxygenase inhibitors blunt it. White willow bark yields salicin, converted in the body to salicylic acid, a weak cyclooxygenase inhibitor. The mechanism is established for aspirin specifically. The willow-derived version is an extrapolation and the salicylate content of an extract varies.

Thiamine pyrophosphate performs the decarboxylation step in the pyruvate and alpha-ketoglutarate dehydrogenase complexes, and NAD+ collects the electrons released at the end of each of those same complexes. Transketolase in the pentose phosphate pathway is likewise thiamine-dependent and feeds the ribose used to build NAD. The two vitamins are structural neighbours in carbohydrate metabolism.